Spectrum of therapy-related clonal cytopenias and neoplasms after exposure to Lutetium-177-Dotatate-Reference-Cited by-同舟云学术

Spectrum of therapy-related clonal cytopenias and neoplasms after exposure to Lutetium-177-Dotatate

Published:2024-01 Issue: Volume:136 Page:107434
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Pritzl Stephanie L.,Kusne Yael,Halfdanarson Thorvardur R.,Hobday Timothy,Sonbol Mohamad Bassam,Kendi Ayse Tuba,Mangaonkar Abhishek A.,Gangat Naseema,Shah Mithun,Patnaik Mrinal M.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference20 articles.

1. Making sense of a complex disease: a practical approach to managing neuroendocrine tumors;Zhang;JCO Oncol. Pract.,2022

2. Assessment of therapy-related myeloid neoplasms in patients with neuroendocrine tumors after peptide receptor radionuclide therapy: a systematic review;Sonbol;JAMA Oncol.,2020

3. Radionuclide therapy for neuroendocrine tumors;Cives;Curr. Oncol. Rep.,2017

4. NETTER-1 trial investigators. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors;Strosberg;N. Engl. J. Med.,2017

5. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors. Version 2.2022. Accessed 3/6/23. https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clonal Hematopoiesis in Patients With Neuroendocrine Tumor Treated With Lutetium-177 and the Risk of Thrombocytopenia: A Prospective Study;JCO Precision Oncology;2024-06

2. Decitabine/lutetium-(177Lu)-oxodotreotide/temozolomide;Reactions Weekly;2024-04-06